Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Total Debt: 2022-2025

Historic Total Debt for Immunocore Holdings (IMCR) over the last 2 years, with Sep 2025 value amounting to $392.6 million.

  • Immunocore Holdings' Total Debt rose 0.54% to $392.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.6 million, marking a year-over-year increase of 0.54%. This contributed to the annual value of $391.0 million for FY2024, which is 714.42% up from last year.
  • Per Immunocore Holdings' latest filing, its Total Debt stood at $392.6 million for Q3 2025, which was up 0.13% from $392.1 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Total Debt registered a high of $438.1 million during Q2 2024, and its lowest value of $47.8 million during Q4 2022.
  • Over the past 3 years, Immunocore Holdings' median Total Debt value was $391.8 million (recorded in 2025), while the average stood at $360.2 million.
  • As far as peak fluctuations go, Immunocore Holdings' Total Debt surged by 714.42% in 2024, and later fell by 10.52% in 2025.
  • Over the past 4 years, Immunocore Holdings' Total Debt (Quarterly) stood at $47.8 million in 2022, then grew by 0.43% to $48.0 million in 2023, then surged by 714.42% to $391.0 million in 2024, then increased by 0.54% to $392.6 million in 2025.
  • Its Total Debt stands at $392.6 million for Q3 2025, versus $392.1 million for Q2 2025 and $391.5 million for Q1 2025.